Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Clinical Trials Network LLC

Neither a doctor nor a teaching hospital

Research payments

$10,227,540

1,516 payments

Through program year 2025, The Clinical Trials Network LLC is reported as receiving $10,227,540 in research payments, across 1,516 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $3,430,169 639
2024 Research $2,612,932 496
2023 Research $4,116,484 367
2022 Research $67,955 14

Breakdown

Who paid Research payments · program years 2022–2025
  1. Genentech, Inc. $7,448,392 709 payments
  2. Bausch Health US, LLC $433,097 258 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $377,080 212 payments
  4. AbbVie, Inc. $375,021 32 payments
  5. Sanofi US Services Inc. $365,936 34 payments
  6. Regeneron Pharmaceuticals, Inc. $249,349 59 payments
  7. Braintree Laboratories, Inc. $244,710 22 payments
  8. Pfizer Inc. $151,608 82 payments
  9. Janssen Research & Development, LLC $105,020 9 payments
  10. Chugai Pharmaceutical Co., Ltd. $100,800 24 payments
Studies the money was for Research payments · program years 2022–2025
  1. Roche Cancer Screening Collection Study $7,052,724 617 payments
  2. Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $406,272 237 payments
  3. A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT as Standard of Care $249,349 59 payments
  4. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $244,710 22 payments
  5. A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) $199,424 46 payments
  6. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment $195,902 17 payments
  7. A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohns Disease $140,332 10 payments
  8. A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine $137,923 4 payments
  9. vixarelimab ulcerative colitis study $123,949 25 payments
  10. Study of DONQ52 in Active Celiac Disease $100,800 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record